Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBITDA Margin (2016 - 2025)

Ultragenyx Pharmaceutical has reported EBITDA Margin over the past 10 years, most recently at 54.65% for Q4 2025.

  • Quarterly EBITDA Margin rose 1963.0% to 54.65% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 79.49% through Dec 2025, up 1622.0% year-over-year, with the annual reading at 79.49% for FY2025, 1622.0% up from the prior year.
  • EBITDA Margin was 54.65% for Q4 2025 at Ultragenyx Pharmaceutical, up from 106.85% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 54.65% in Q4 2025 and troughed at 248.14% in Q3 2022.
  • The 5-year median for EBITDA Margin is 108.62% (2021), against an average of 120.83%.
  • Year-over-year, EBITDA Margin soared 22511bps in 2021 and then plummeted -13812bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 122.99% in 2021, then decreased by -15bps to 140.91% in 2022, then soared by 32bps to 95.83% in 2023, then increased by 22bps to 74.28% in 2024, then grew by 26bps to 54.65% in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBITDA Margin are 54.65% (Q4 2025), 106.85% (Q3 2025), and 64.8% (Q2 2025).